Advertisement
Advertisement
U.S. markets close in 36 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Abeona Therapeutics Inc. (ABEO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.8800+0.1200 (+3.19%)
As of 03:21PM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close3.7600
Open3.6600
Bid3.8600 x 1000
Ask3.9300 x 1000
Day's Range3.6600 - 3.9500
52 Week Range0.2700 - 17.0000
Volume220,038
Avg. Volume495,783
Market Cap66.642M
Beta (5Y Monthly)1.26
PE Ratio (TTM)0.10
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ABEO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Abeona Therapeutics Inc.
    Analyst Report: Merck & Co., Inc.Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
    Rating
    Fair Value
    Economic Moat
    20 hours agoMorningstar
View more
  • Benzinga

    Cantor Bullish On Abeona Saying Recent Trial Data 'Best Case Scenario'

    Cantor Fitzgerald raised the price target on Abeona Therapeutics Inc (NASDAQ: ABEO) from $22 to $40 after adjusting the market model/ increasing the probability of success for EB-101. Last week, the company reported topline data from the pivotal Phase 3 VIITAL study of EB-101 for recessive dystrophic epidermolysis bullosa (RDEB). The study met its two co-primary efficacy endpoints demonstrating statistically significant, clinically meaningful improvements in wound healing and pain reduction in l

  • Benzinga

    Abeona Therapeutics Touts Positive Data From Pivotal EB-101 Study In Blistering Skin Disorder

    Abeona Therapeutics Inc (NASDAQ: ABEO) announced topline data from its pivotal Phase 3 VIITAL study of EB-101 for recessive dystrophic epidermolysis bullosa (RDEB). The VIITAL study met its two co-primary efficacy endpoints demonstrating statistically significant, clinically meaningful improvements in wound healing and pain reduction in large chronic RDEB wounds. EB-101 significantly improved wound healing vs. control at six months. In addition to meeting the co-primary pain endpoint, in a post-

  • Insider Monkey

    10 Best Penny Stocks to Buy in September

    In this article, we discuss 10 best penny stocks to buy in September. If you want to see more stocks in this selection, check out 5 Best Penny Stocks to Buy in September. As the stock market runs red, investors are wary about spending copious amounts of money and making huge investments amid such macro […]

Advertisement
Advertisement